David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
This activity will explore the management of patients with HER2-negative, metastatic gastric cancer and the emerging role of immunotherapy as a first-line treatment option.
This activity is designed to meet the educational needs of medical oncologists, pathologists, internal medicine physicians, and others (eg, nurse practitioner, pharmacist, physician assistant, oncology nurse) involved in the management of patients with gastric cancer.
After completing the CME activity, learners should be better able to:
- Review the current first-line treatment options for patients with HER2-negative, metastatic gastric cancer
- Discuss the use and interpretation of immuno-biomarkers in the evaluation of patients with metastatic gastric cancer
- Review emerging the clinical trials data for immunochemotherapy combinations as first-line therapy in patients with metastatic, HER2-negative gastric carcinoma
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Conference Complete Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with metastatic gastric carcinoma.
Credits: 0.75 ANCC Contact Hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
David H. Ilson, MD, PhD, serves as consultant to Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Pieris, Roche, and Taiho Pharmaceutical Group. He serves on the Data Safety Monitoring Board for IQVIA and Merck. He discloses other commercial interests with MacroGenics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the enduring activity; and
- Complete pre- and post-surveys and evaluation.
You will receive your certificate as a downloadable certificate.
Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
RELEASE DATE: March 26, 2021
EXPIRATION DATE: March 26, 2022
Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.